STO:ONCO

Oncopeptides AB (publ) · STO · Healthcare · SEK · FY for 2025

Figures on this page computed 2026-11-08 12:48 UTC

Last close

n/aSEK

Market data

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
SEK
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
SEK
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
-350.9%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
SEK
- Computed from the filing for 2025
- Computed from the filing for 2025
-313.4%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
SEK
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
SEK
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
SEK
- computed

Safety is the furthest below its sector's middle: 0.32 against 0.52 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.34x

0.44x

0.41x

2.14x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales1.34x
Its own average over 5 years, 52.9M.
Profit0.44x
Its own average over 10 years, -566.8M.
Free cash flow0.41x
Its own average over 10 years, -542.2M.
Debt2.14x
Its own average over 7 years, 65.3M.
Pricen/a
Its own average over 0 years. Market data

Debt is furthest from its own average, at 2.13 times.

Sales is 1.34 times its own 5-year average; Profit is 0.44 times its own 10-year average; Free cash flow is 0.41 times its own 10-year average; Debt is 2.13 times its own 7-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales against its own 5-year average1.34
Source
computed
Statement
income
Fiscal year
2025
Reported in
SEK
Profit against its own 10-year average0.44
Source
computed
Statement
income
Fiscal year
2025
Reported in
SEK
Free cash flow against its own 10-year average0.41
Source
computed
Statement
income
Fiscal year
2025
Reported in
SEK
Debt against its own 7-year average2.14
Source
computed
Statement
income
Fiscal year
2025
Reported in
SEK
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
SEK